biostudies-literatureRenda GNational Institute for Health Research (NIHR)Università di PisaDaiichi Sankyo Europe GmbH591-599https://www.ebi.ac.uk/biostudies/studies/S-EPMC8049932biostudies-literatureUnknown16(3)The management of patients with atrial fibrillation (AF) has rapidly changed with increasing use of non-vitamin K antagonist oral anticoagulants (NOACs) and changes in the use of rhythm control therapy. The prevention of thromboembolic events European Registry in Atrial Fibrillation Prolongation Registry (PREFER Prolongation) enrolled consecutive patients with AF on NOACs between 2014 and 2016 in a multicentre, prospective, observational study with one-year follow-up, focusing on the time of introduction of NOACs. Overall, 3783 patients were enrolled, with follow-up information available in 3223 (85%). Mean age was 72.2 ± 9.4 years, 40% were women, mean CHA₂DS₂VASc score was 3.4 ± 1.6, and 2587 (88.6%) had a CHA₂DS₂VASc score ≥ 2. Rivaroxaban wasInternal and emergency medicineAntithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry.PMC8049932NIHR132974NIHR130280CDF-2015-08-074Schnabel RBWachter RZamorano JLDe Caterina RDarius HRenda GPecen LPatti GLucerna MHuber KKotecha DRicci FBruggenjurgen BDuytschaever MSiller-Matula JMLe Heuzey JYRohla MVerheugt FWASchilling RJKirchhof PSellal JMfalseAntithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry.The management of patients with atrial fibrillation (AF) has rapidly changed with increasing use of non-vitamin K antagonist oral anticoagulants (NOACs) and changes in the use of rhythm control therapy. The prevention of thromboembolic events European Registry in Atrial Fibrillation Prolongation Registry (PREFER Prolongation) enrolled consecutive patients with AF on NOACs between 2014 and 2016 in a multicentre, prospective, observational study with one-year follow-up, focusing on the time of introduction of NOACs. Overall, 3783 patients were enrolled, with follow-up information available in 3223 (85%). Mean age was 72.2 ± 9.4 years, 40% were women, mean CHA₂DS₂VASc score was 3.4 ± 1.6, and 2587 (88.6%) had a CHA₂DS₂VASc score ≥ 2. Rivaroxaban was2021-01-01T00:00:00Z2021 Apr2025-04-04T18:37:04.136Z2022-02-09T17:47:48.458ZS-EPMC80499323295567710.1007/s11739-020-02442-9